Score Overview
See the full market ranking β
Johnson & Johnson fundamental performance
Between 2020 and 2025, revenue grew from $ 82.58B to $ 94.19B and net income grew from $ 14.71B to $ 26.80B. Revenue increased in every one of those 5 years; net income in 2.
Across Johnson & Johnson's full reported history, from 1985 to 2025, revenue grew from $ 6.42B to $ 94.19B and net income grew from $ 613M to $ 26.80B. Revenue increased in 90% of the years measured; net income in 68%.
Johnson & Johnson currently holds a 20-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 260.86 | β |
1 Year2025-08-12 | $ 168.55 | 54.77% |
5 Years2021-08-12 | $ 152.20 | 71.39% |
10 Years2016-08-12 | $ 93.71 | 178.36% |
20 Years2006-08-11 | $ 35.56 | 7x |
30 Years1996-08-12 | $ 12.62 | 20x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 |
|---|---|---|---|---|---|---|
| Price | $ 260.86 | $ 168.55 | $ 152.20 | $ 93.71 | $ 35.56 | $ 12.62 |
| Return | β | 54.77% | 71.39% | 178.36% | 7x | 20x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 96.36B | $ 21.04B | $ 22.05B |
| 2025 | $ 94.19B | $ 26.80B | $ 20.10B |
| 2024 | $ 88.82B | $ 14.06B | $ 24.52B |
| 2023 | $ 85.15B | $ 35.15B | $ 22.92B |
| 2022 | $ 79.99B | $ 17.94B | $ 22.28B |
| 2021 | $ 78.74B | $ 20.87B | $ 31.60B |
| 2020 | $ 82.58B | $ 14.71B | $ 25.18B |
| 2019 | $ 82.05B | $ 15.11B | $ 19.28B |
| 2018 | $ 81.58B | $ 15.29B | $ 19.68B |
| 2017 | $ 76.45B | $ 1.30B | $ 18.29B |
| 2016 | $ 71.89B | $ 16.54B | $ 41.90B |
| 2015 | $ 70.07B | $ 15.40B | $ 38.37B |
| 2014 | $ 74.33B | $ 16.32B | $ 33.08B |
| 2013 | $ 71.31B | $ 13.83B | $ 29.20B |
| 2012 | $ 67.22B | $ 10.85B | $ 21.08B |
| 2011 | $ 65.03B | $ 9.67B | $ 32.26B |
| 2010 | $ 61.58B | $ 13.33B | $ 27.65B |
| 2009 | $ 61.89B | $ 12.26B | $ 19.42B |
| 2008 | $ 63.74B | $ 12.94B | $ 12.80B |
| 2007 | $ 61.09B | $ 10.57B | $ 9.31B |
| 2006 | $ 53.32B | $ 11.05B | $ 4.08B |
| 2005 | $ 50.51B | $ 10.06B | $ 16.13B |
| 2004 | $ 47.34B | $ 8.18B | $ 12.88B |
| 2003 | $ 41.86B | $ 7.19B | $ 9.52B |
| 2002 | $ 36.29B | $ 6.59B | $ 7.47B |
| 2001 | $ 32.31B | $ 5.66B | $ 7.97B |
| 2000 | $ 29.17B | $ 4.95B | $ 6.75B |
| 1999 | $ 28.00B | $ 4.27B | $ 3.87B |
| 1998 | $ 23.99B | $ 3.00B | $ 2.78B |
| 1997 | $ 22.62B | $ 3.30B | $ 2.75B |
| 1996 | $ 21.62B | $ 2.88B | $ 2.01B |
| 1995 | $ 18.84B | $ 2.40B | $ 1.20B |
| 1994 | $ 15.73B | $ 2.00B | $ 636M |
| 1993 | $ 14.13B | $ 1.78B | $ 372M |
| 1992 | $ 13.75B | $ 1.03B | $ 745M |
| 1991 | $ 12.44B | $ 1.46B | $ 589M |
| 1990 | $ 11.23B | $ 1.14B | $ 826M |
| 1989 | $ 9.75B | $ 1.08B | $ 452M |
| 1988 | $ 9.00B | $ 974M | $ 660M |
| 1987 | $ 8.01B | $ 833M | $ 741M |
| 1986 | $ 7.00B | $ 329M | $ 952M |
| 1985 | $ 6.42B | $ 613M | $ 735M |
Explore beyond JNJ
You're looking at Johnson & Johnson. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score β 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
Explore other companies
- Alnylam Pharmaceuticals IncALNYΒ· revenue grew in 70% of years
- Dr. Reddyβs Laboratories Ltd ADRRDYΒ· revenue grew in 80% of years
- Bio-Rad Laboratories IncBIOΒ· revenue grew in 75% of years
- Haemonetics CorporationHAEΒ· revenue grew in 75% of years
- AMN Healthcare Services IncAMNΒ· revenue grew in 75% of years
